POST Online Media Lite Edition



 

NEWLY REPORTED COVID-19 CASES (11.19.2021, 4:50pm CEST, WHO):   India 11,106    Brazil 11,977    United Kingdom 46,858    Russia 37,156    Turkey 22,234    France 19,840    Argentina 1,553    Germany 52,970    Spain 3,932    Columbia 2,257    Italy 10,645    Mexico 3,836    Ukraine 20,050    Poland 23,242    Philippines 1,297    Malaysia 6,380    Netherlands 23,680    Peru 1,370    Thailand 6,855    Czechia 13,374    Canada 2,448    Romania 3,076    Chile 2,611    Serbia 3,219    Sweden 1,210    Portugal 2,398    Vietnam 10,223    Kazakhstan 1,272    Austria 14,212    Hungary 11,289    Greece 7,276    Georgia 4,278    Bulgaria 2,785    Belarus 1,844    Slovakia 7,418    Azerbaijan 2,124    Croatia 7,270    Bolivia 1,119    Ireland 4,646    Lithuania 1,847    Denmark 4,013    South Korea 3,034    Slovenia 3,662    Latvia 1,221    Laos 1,401    China 31    New Zealand 200    Australia 1,302   

FDA: Homeopathic products are risk, we didn't approve them

Christian Fernsby |
The U.S. Food and Drug Administration has posted warning letters to five companies who produce products labeled as homeopathic for significant violations of current good manufacturing practice (CGMP) regulations.

Article continues below




Four of the warning letters pertain to companies who jointly produced a product labeled as homeopathic that posed a significant safety risk to consumers because their purportedly sterile products were not shown to be sterile.

An additional letter outlines a company’s failure to have systems in place to assure proper design, monitoring, and control of manufacturing processes.

Products labeled as homeopathic have not been approved by the FDA for any use and may not meet modern standards for safety, effectiveness and quality.

Products labeled as homeopathic can be made from a wide range of substances, including ingredients derived from plants; healthy or diseased animal or human sources; minerals and chemicals.

These products are often marketed as natural, safe and effective alternatives to approved prescription and nonprescription products and are widely available in the marketplace.

These unapproved drugs may cause significant and even irreparable harm if they are poorly manufactured, which can lead to contamination, or may contain active ingredients that are not adequately tested or disclosed to patients.

The warning letters issued to Kadesh, U.S.

Continental Marketing, Fill It Pack It, and Bershtel Enterprises, doing business as WePackItAll, describe failures to conform to CGMP requirements due to improper methods, facilities or controls for manufacturing, processing and packing.

These companies jointly manufacture and package Puriton Eye Relief Drops, which are labeled as homeopathic.

The FDA tested multiple samples and found these eye drops were non-sterile, which could lead to an eye infection, and had a high pH level, which could lead to eye injury such as glaucoma, corneal scarring and loss of vision.

Kadesh issued a voluntary recall in November 2018 due to non-sterile production conditions at the manufacturing facility.

Another warning letter was issued to Newton Laboratories for human drug CGMP and misbranding violations, as well as unapproved new animal drug violations.

Some of the company’s products labeled as homeopathic are indicated for treating conditions in infants and children, and they are manufactured from ingredients such as nux vomica, belladonna, aconitum napellus, and gelsemium sempervirents that pose potentially toxic effects.

For example, nux vomica contains strychnine, which is a highly toxic, well-studied poison that is used to kill rodents.

Producing such a product without proper manufacturing controls may lead to super-potent drugs, which could be a potential poisoning risk for consumers.


What to read next

FDA seeks permanent injunctions against two stem cell clinics
99% doctors have recommended natural remedies for children
Dramatic increase in e-cigarette use among youth in U.S.